Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA)


IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best healthcare stocks with the highest upside. Citizens JMP analyst Silvan Tuerkcan released a rating update for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) on October 13, maintaining a Buy rating for the stock with a price target of $45.

IDEAYA Biosciences (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform
IDEAYA Biosciences (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) also received a bullish rating from J.P. Morgan analyst Anupam Rama on September 23, who assigned the stock a Buy rating with a $74 price target.

The analyst based the rating on several promising developments associated with the company’s lead asset, darovasertib, stating that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is anticipated to release notable updates on darovasertib in several treatment settings. This is expected to support significant value creation.

Darovasertib is a small molecule for patients with uveal melanoma, which is a rare type of eye cancer with considerable unmet medical need.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) develops oncology-focused precision medicine, focusing on targeted therapeutics for patients selected using molecular diagnostics. The company’s product candidate is IDE196, a protein kinase C inhibitor that targets genetically defined cancers with GNAQ or GNA11 gene mutations.

While we acknowledge the potential of IDYA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *